Mortality in Patients With Sepsis Treated With Esmolol or Landiolol: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis
Pooled result · Very low certainty of the evidenceResult — go to the resultRelative risk 0.84 95% CI 0.68–1.02Authors' conclusion
In this updated meta-analysis, the use of esmolol or landiolol did not reduce mortality in patients with sepsis with persistent tachycardia.
Study context
- Population
- Adults with sepsis with persistent tachycardia
- Participants
- 885 adults · 8 randomized controlled trials (RCTs)
- Comparison
- Esmolol or landiolol vs neither or placebo
- Outcome
- Mortality at the longest follow-up
Methodological detailsrandom effects model, trial sequential analysis, updated meta-analysis
- Random effects model
- Trial sequential analysis
- Updated meta-analysis
Pooled result
Very low certainty of the evidence · longest follow-up
Relative risk
0.84
95% CI 0.68–1.02
P = 0.08
Esmolol or landiolol vs Control
RR 0.84 (95% CI 0.68–1.02); P = 0.08
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| 28-day mortality · I2 = 62% | 0.77 (0.59–1.00) | P = 0.05 | |
| 0.512Relative risk (log scale) |
Mortality, single-centre vs multicentre RCTs (subgroup)
- Different results between single-center and multicenter RCTs
Mortality, adding non-English RCTs (sensitivity analysis)
- Significant reduction in mortality
Original publication
Mortality in Patients With Sepsis Treated With Esmolol or Landiolol: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis. Chest. Published 26 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →